Syndax Pharmaceuticals (SNDX) Gross Margin (2024 - 2026)

Syndax Pharmaceuticals' Gross Margin history runs 3 years deep, the most recent figure standing at 81.74% for Q1 2026.

• In Q1 2026, Gross Margin fell 1385.0% year-over-year to 81.74%; the TTM figure through Mar 2026 stood at 98.07% (up 199.0% YoY), while the FY2025 annual figure was 95.96%, down 56.0% from the prior year.
• Gross Margin for Q1 2026 stood at 81.74%, down from 125.05% in the prior quarter.
• The five-year high for Gross Margin was 125.05% in Q4 2025, with the low at 81.74% in Q1 2026.
• The 3-year median for Gross Margin is 96.11% (2025), against an average of 96.27%.
• Peak annual rise in Gross Margin reached 3580 bps in 2025, while the deepest fall reached 1806 bps in 2025.
• Syndax Pharmaceuticals' Gross Margin stood at 89.24% in 2024, then soared by 40 bps to 125.05% in 2025, then plunged by 35 bps to 81.74% in 2026.
• Business Quant data shows SNDX's Gross Margin at 81.74% in Q1 2026, 125.05% in Q4 2025, and 81.94% in Q3 2025.